• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗患者的诊室血压与缺血和出血事件的关联。

Association of office blood pressure with ischemic and bleeding events in patients undergoing percutaneous coronary intervention.

机构信息

Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea.

Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Seoul Hospital, 222 Wangsimni-ro, Sungdong-gu, Seoul, 04763, Republic of Korea.

出版信息

Sci Rep. 2024 Sep 2;14(1):20310. doi: 10.1038/s41598-024-71060-8.

DOI:10.1038/s41598-024-71060-8
PMID:39218965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11366747/
Abstract

Optimal blood pressure (BP) for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) remains unclear. This study aims to identify the optimal BP by investigating the association between average office BP and future clinical events in patients undergoing PCI. Consecutive patients undergoing PCI from 2012 to 2016 were included. They were divided into five groups according to the average follow-up BP after discharge. The co-primary outcomes were net adverse clinical events (NACE) and major adverse cardiac and cerebrovascular events (MACCE) up to 5 years. NACE was defined as a composite of MACCE (all-cause death, non-fatal myocardial infarction (MI), non-fatal stroke, or any revascularization) or major bleeding. A total of 2845 patients were included, and among them, 787 (27.7%) experienced the NACE during the follow-up period. Patients in the highest SBP group (adjusted hazard ratio [HR] 1.495, confidence interval [CI] 1.189-1.880) and lowest SBP group (adjusted HR 1.625, CI 1.214-2.176) had a significantly higher risk of 5-year NACE. Similar associations were observed between SBP and the risk of MACCE, and similar results based on DBP categories were also observed. There was a J-curve relationship between SBP and DBP with respect to 5-year NACE and MACCE. The nadir point of risk for NACE and MACCE was found at 121.4/74.8 and 120.4/73.7 mmHg. In patients underwent PCI, there is a significant correlation between office BP level and clinical events, indicates the importance of efforts for optimal BP control to reduce ischemic and bleeding events.Trial registration: HanYang University Medical Center (HYUMC) Registry, NCT05935397.

摘要

在接受经皮冠状动脉介入治疗(PCI)的冠心病(CAD)患者中,最佳血压(BP)仍不清楚。本研究旨在通过研究 PCI 后平均诊室 BP 与未来临床事件之间的关系来确定最佳 BP。

连续纳入 2012 年至 2016 年接受 PCI 的患者。根据出院后随访 BP 的平均值,将其分为五组。主要复合终点为 5 年内的净不良临床事件(NACE)和主要不良心脏和脑血管事件(MACCE)。NACE 定义为 MACCE(全因死亡、非致死性心肌梗死(MI)、非致死性卒中和任何血运重建)或大出血的复合终点。共纳入 2845 例患者,其中 787 例(27.7%)在随访期间发生 NACE。SBP 最高组(校正后的危险比 [HR] 1.495,置信区间 [CI] 1.189-1.880)和最低 SBP 组(校正后的 HR 1.625,CI 1.214-2.176)发生 5 年 NACE 的风险显著升高。SBP 与 MACCE 风险之间也存在类似的关联,基于 DBP 分类也观察到类似的结果。SBP 和 DBP 与 5 年 NACE 和 MACCE 之间存在 J 形关系。NACE 和 MACCE 风险的最低点在 121.4/74.8 和 120.4/73.7mmHg。在接受 PCI 的患者中,诊室 BP 水平与临床事件之间存在显著相关性,表明努力控制最佳 BP 以减少缺血和出血事件的重要性。

试验注册

韩阳大学医疗中心(HYUMC)登记处,NCT05935397。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/aad9cdaba13f/41598_2024_71060_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/10d06a8fe65a/41598_2024_71060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/1025013d4176/41598_2024_71060_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/cbe86ed27e72/41598_2024_71060_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/25e3893a8a01/41598_2024_71060_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/aad9cdaba13f/41598_2024_71060_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/10d06a8fe65a/41598_2024_71060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/1025013d4176/41598_2024_71060_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/cbe86ed27e72/41598_2024_71060_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/25e3893a8a01/41598_2024_71060_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c419/11366747/aad9cdaba13f/41598_2024_71060_Fig5_HTML.jpg

相似文献

1
Association of office blood pressure with ischemic and bleeding events in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者的诊室血压与缺血和出血事件的关联。
Sci Rep. 2024 Sep 2;14(1):20310. doi: 10.1038/s41598-024-71060-8.
2
Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes.ST 段抬高型心肌梗死合并糖尿病患者多支冠状动脉病变行分期完全血运重建或罪犯血管单纯经皮冠状动脉介入治疗。
Cardiovasc Diabetol. 2019 Sep 17;18(1):119. doi: 10.1186/s12933-019-0923-0.
3
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.高出血风险患者接受复杂经皮冠状动脉介入治疗后抗血小板治疗的持续时间:MASTER DAPT试验的亚组分析
Eur Heart J. 2022 Sep 1;43(33):3100-3114. doi: 10.1093/eurheartj/ehac284.
4
Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.比较经皮冠状动脉介入治疗的糖尿病患者和非糖尿病患者中 P2Y12 抑制剂单药治疗与双联抗血小板治疗的疗效和安全性。
Int J Mol Sci. 2022 Apr 20;23(9):4549. doi: 10.3390/ijms23094549.
5
Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).三维分叉角度对左主干冠状动脉疾病经皮冠状动脉介入治疗后 5 年预后的影响:SYNTAX 试验(紫杉醇药物洗脱支架与心脏搭桥术的联合治疗)的一项亚组研究。
JACC Cardiovasc Interv. 2013 Dec;6(12):1250-60. doi: 10.1016/j.jcin.2013.08.009.
6
Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.东亚患者经皮冠状动脉介入治疗后血小板反应性与缺血和出血事件的关系:PENDULUM 登记研究的 1 年结果。
J Am Heart Assoc. 2020 May 18;9(10):e015439. doi: 10.1161/JAHA.119.015439. Epub 2020 May 12.
7
Effects of Body Weight on Bleeding and Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention - From the CREDO-Kyoto Registry Cohort-2.体重对行经皮冠状动脉介入治疗患者出血和缺血事件的影响——来自 CREDO-Kyoto 注册研究队列-2。
Circ J. 2020 Sep 25;84(10):1734-1745. doi: 10.1253/circj.CJ-20-0343. Epub 2020 Sep 5.
8
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.经皮冠状动脉介入治疗后比伐卢定输注与净不良临床事件的关系:GLOBAL LEADERS 研究的事后分析。
Eur Heart J Cardiovasc Pharmacother. 2020 Jan 1;6(1):22-30. doi: 10.1093/ehjcvp/pvz051.
9
[Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].[经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗无保护左主干冠状动脉分叉病变的长期预后比较]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jan 25;45(1):19-25. doi: 10.3760/cma.j.issn.0253-3758.2017.01.005.
10
Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial.心房颤动合并稳定型冠状动脉疾病患者的出血事件及其对心血管事件和死亡的影响:来自 AFIRE 试验的观察。
Circ Cardiovasc Interv. 2021 Nov;14(11):e010476. doi: 10.1161/CIRCINTERVENTIONS.120.010476. Epub 2021 Sep 3.

引用本文的文献

1
Association of systolic blood pressure target and variability with long-term clinical outcomes in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者的收缩压目标值及变异性与长期临床结局的关联
Clin Hypertens. 2025 Apr 1;31:e13. doi: 10.5646/ch.2025.31.e13. eCollection 2025.

本文引用的文献

1
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.急性冠状动脉综合征和经皮冠状动脉介入治疗中双联抗血小板治疗的降级或缩短:来自冠状动脉血栓形成国际专家小组的共识声明。
Nat Rev Cardiol. 2023 Dec;20(12):830-844. doi: 10.1038/s41569-023-00901-2. Epub 2023 Jul 20.
2
The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension.《2018年韩国高血压学会高血压管理指南》2022年重点更新版
Clin Hypertens. 2023 Feb 15;29(1):11. doi: 10.1186/s40885-023-00234-9.
3
Blood pressure and mortality after percutaneous coronary intervention: a population-based cohort study.
经皮冠状动脉介入治疗后的血压与死亡率:一项基于人群的队列研究。
Sci Rep. 2022 Feb 17;12(1):2768. doi: 10.1038/s41598-022-06627-4.
4
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2021 ACC/AHA/SCAI 冠状动脉血运重建指南:美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129. doi: 10.1016/j.jacc.2021.09.006. Epub 2021 Dec 9.
5
Intraoperative hypotension and complications after vascular surgery: A scoping review.血管手术后术中低血压与并发症:范围综述。
Surgery. 2021 Jul;170(1):311-317. doi: 10.1016/j.surg.2021.03.054. Epub 2021 May 7.
6
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.使用凝血酶拮抗剂达比加群或华法林进行长期抗凝治疗的患者的心血管结局、出血风险及血压达标情况:来自RE-LY试验的数据
Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
7
Trends in Characteristics and Outcomes of Patients Undergoing Coronary Revascularization in the United States, 2003-2016.2003-2016 年美国冠状动脉血运重建患者特征和结局的变化趋势。
JAMA Netw Open. 2020 Feb 5;3(2):e1921326. doi: 10.1001/jamanetworkopen.2019.21326.
8
High Blood Pressure and Cardiovascular Disease.高血压与心血管疾病。
Hypertension. 2020 Feb;75(2):285-292. doi: 10.1161/HYPERTENSIONAHA.119.14240. Epub 2019 Dec 23.
9
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.接受 PCI 治疗的 ACS 患者的平均每日缺血与出血风险:来自 BleeMACS 和 RENAMI 登记研究的见解。
Am Heart J. 2020 Feb;220:108-115. doi: 10.1016/j.ahj.2019.10.001. Epub 2019 Nov 11.
10
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗三血管病变或左主干病变患者:多中心随机对照 SYNTAX 试验 10 年随访结果。
Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.